drugset / Trial / NCT01049984

Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

NCT01049984

Phase 4 Completed 328 enrolled Teva Neuroscience, Inc. H. Lundbeck A/S · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To assess the efficacy of rasagiline 1 mg as a first add-on treatment to dopamine agonist therapy in early Parkinson Disease (PD) patients, , not optimally controlled on dopamine agonists as compared to placebo.

Timeline

Start
2009-12
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Rasagiline Small molecule 1 mg Oral

Indications